Epidemiology & market evaluation
Sizing disease burden, incidence and prevalence, and addressable opportunity using NHS and open UK datasets — framed for forecasting, access planning, and launch prioritisation.
Showroom
Related live demos
Open working examples in context — supplementary to a conversation, not a substitute for scoping your own datasets and governance.
- Embedded analytics — illustrated with obesity in England
Embedded analytics showcase
Eye4Health delivers interrogable analytics inside a governed, on-brand web experience — so medical, market access, and brand teams share one evidence story in workshops and planning. Below is a live illustration on open public-health data; commissioned work uses your sources, controls, and narrative.
- Oncology pathways — embedded Power BI (open NHS data)
Power BI pathway insight demo
Live showroom embed exploring oncology patient pathway dynamics from openly published NHS data — variation in diagnosis, referral, and management signals presented in Power BI inside Eye4Health’s governed, on-brand surface.
- AATD prevalence — population planning demo
AATD prevalence planning demo
Live prototype for alpha-1 antitrypsin deficiency (AATD): translate population size and cited prevalence scenarios into expected case counts — with optional confidence ranges, visible methodology, and assumptions you can defend in workshops.
- AATD Case-Finder — governed decision-support demo
AATD decision-support demo
Live prototype of how Eye4Health structures alpha-1 antitrypsin deficiency (AATD) testing prompts: enter clinical flags, see explainable outputs with rationale and next steps, and evidence-linked logic you can govern — all without storing identifiers.
The problem we see
Leadership needs a defensible view of where need sits, how it is changing, and what is measurable with available data — not a slide of charts without a decision attached.
Outcome we work towards: Clear market narratives backed by transparent methods, reproducible cuts, and assumptions your medical and commercial teams can stress-test.
Business questions
- Where is the real addressable population for this indication, by geography and care setting?
- How do prevalence, diagnosis, treatment, and outcomes trajectories compare across nations and systems?
- Which datasets are credible for the question — and what are the known gaps and biases?
What Eye4Health delivers
- Burden and opportunity sizing with documented definitions and sensitivity checks
- Geographic and pathway views aligned to account planning and access questions
- Scenario-ready outputs for forecasting, launch readiness, and evidence planning
Data and methods
- NHS and UK open datasets (e.g. prevalence, activity, prescribing where appropriate), selected international references where useful
- Transparent coding of cohorts, geographies, and time windows; reconciliation notes where sources disagree
- Structured assumptions register so teams can rerun scenarios as evidence evolves
Who this is for
- Medical and commercial leadership preparing evidence and narrative for access and launch
- Market access and HEOR teams building an externally credible storyline
- Forecasting and brand teams needing a shared baseline the organisation can align on
Example outcome (anonymised)
An anonymised engagement combined disease burden, treatment dynamics, and geography to prioritise where access barriers were likely to bite first — informing both resourcing and evidence generation.
Related insights
Next step
If this matches a live decision on your side, a short working session usually clarifies scope fast — without a generic “sales deck” detour.